Pharmacophores, three-dimensional arrangements of chemical groups essential for biological activity, are being proposed in increasing numbers. We have developed a system to search data bases of three-dimensional coordinates for compounds that contain a particular pharmacophore. The coordinates can be derived from experiment (e.g., Cambridge Crystal Database) or be generated from data bases of connection tables (e.g., Cyanamid Laboratories proprietary compounds) via the program CONCORD. We discuss the results of searches for three sample pharmacophores. Two have been proposed by others based on the conformational analysis of active compounds, and one is inferred from the crystal structure of a protein-igand complex. These examples show that such searches can identify classes of compounds that are structurally different from the compounds from which the pharmacophore was derived but are known to have the appropriate biological activity. Occasionally, the searches find bond "frameworks" in which the important groups are rigidly held in the proper geometry. These may suggest new structural classes for synthesis.
The function of rational drug design is to relate chemical structure to a specific biological activity and then to use the relationship to select existing compounds for testing or to suggest new compounds for synthesis. Now that threedimensional molecular modeling is widely used, "pharmacophore" models for a variety of biological activities are appearing in the literature in increasing numbers. The concept of a pharmacophore, although based on many simplifying assumptions, is a useful one: a particular spatial arrangement of chemical groups (usually atoms), common to all active molecules, that is recognized by a single receptor. Pharmacophores can be inferred from the structure ofligandreceptor complexes or, when the structure of the receptor is not known, can be deduced by conformational analysis of active compounds, as in the "active analog" approach (1) (2) (3) . A pharmacophore is usually expressed in three-dimensional terms (distances, angles, volumes), and its atoms may be described by a physical property (cation, hydrogen bond donor, etc.). Often, a pharmacophore will contain one or more "dummy" atoms, which are used to define a geometric entity (centroid of a ring, a lone pair direction, etc.).
More than 10 years ago, Gund (4, 5) pointed out how, once a pharmacophore is defined for a particular biological activity, one could gain further insight by finding structures that contain the pharmacophore but are structurally different from the compounds from which the pharmacophore was derived. He described one of the first methods (MOLPAT) to search for pharmacophores in data bases of threedimensional coordinates. At that time, the usefulness of such searches was limited since the three-dimensional data bases available (crystal coordinates or computer-generated conformations of a few compounds) were -mall. Now, however, the data base of crystal coordinates maintained by Cambridge (6) has >60,000 entries. Moreover, practical methods to transform large data bases of connection tables to coordinate form (7) have recently become available. Also, computer algorithms for doing three-dimensional substructure searches (8-10) have improved.
Searching for pharmacophores in large data bases has now become a practical way to exploit geometric structureactivity information. In this paper, we discuss the results of searching for three sample pharmacophores. Our primary goal is to demonstrate the type of insight that can come from pharmacophore searches.
METHODS
We have been working with two large data bases of coordinates: CCD, a subset of the Cambridge Crystal Database (6), and CLFIL, a three-dimensional version of the CL File, the set of proprietary structures from American Cyanamid. The 29,828 structures in CCD are those for which we could relate the coordinate and connection table information provided by the Cambridge Crystallographic Data Centre. The 223,988 structures in CLFIL were generated from a MACCS data base by using CONCORD. [MACCS (Molecular ACCess System) is the tradename for a chemical data base management system supplied by Molecular Design Ltd., San Leandro, CA.] CONCORD is a rule-based system that generates a single set of three-dimensional coordinates from a connection table that contains only "organic" atoms. Structures in either data base are stored as a set of atom types and coordinates for nonhydrogen atoms. The atom type consists of five fields: element, number of neighbors (i.e., bonded atoms), the number of pi electrons, the number of attached hydrogens at physiological pH, and formal charge. Four types of dummy atoms were added: D5 and D6 (the centroids of planar 5-and 6-membered rings), DP (along the perpendiculars to these rings), and DL (attached to each heteroatom along the vector sum of the bonds from its neighbors). These are equivalent to the types of dummy atoms most often used in describing pharmacophore geometries. Details of how the data bases were generated will be given elsewhere (7) .
We have developed a system 3DSEARCH (8) that allows a user to define a three-dimensional substructure "query," a set of atoms and a -description of the spatial relationship between them, and to search for it in large data bases of coordinates. The user can specify upper and lower bounds to selected distances, angles, and dihedral angles. Excluded volumes (regions that are not allowed to be occupied) can also be taken into account. We can define several possible atom types for each query atom, making it possible to specify "generic" types (cations, hydrogen-bond donors, etc).
Abbreviations: CNS, central nervous system; ACE, angiotensinconverting enzyme.
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For this example, we searched both the CCD and the CLFIL and found 18 and 100 hits, respectively. Selected structures are shown in Fig. 2b . In the CCD we found the known ACE inhibitors captopril (MCPRPL), YS-980 (DI-VHEV), and enalaprilat (CIYNIH). In the CLFIL we found captopril, an analog of captopril (CL232735) made in-house as part of our antihypertensive program (16) , and three structures resembling enalaprilat. These structures are closely related to the compounds Mayer et al. used to generate the pharmacophore. It is interesting that a few dipeptides are also found in each data base [e.g., Glu-Val, Glu-Leu, and Glu-Lys in CLFIL and Cys-Gly (CYGNAI) in CCD]. Cheung et al. (17) measured the binding of selected dipeptides as possible inhibitors of ACE. None of the peptides mentioned above were tested. However, mercaptopropanoylcysteine, which differs from Cys-Gly only because it lacks the amino nitrogen, bound in the micromolar range. This suggests that further insight might be expected from testing dipeptides of the form Cys-Xaa. Unexpectedly, we found in both data bases a series of dicarboxypyrazines and -pyridines (e.g., APDPZC in CCD), structures in which the essential atoms are locked in the pharmacophore geometry. The superposition of selected hits is shown in Fig. 3 .
Our third example is derived from the known structure of a ligand-protein complex. The tryptophan-tryptophan repressor complex has been solved at 2.6-A resolution (18) and is available as the data set 1WRP in the Brookhaven Protein Databank (19) . Fig. ic shows For this example, we want to find structures that contain the pharmacophore and fit into the binding site with little or no steric clash with the protein. Therefore, the volume within 2.4 A of any of the 122 protein atoms within 7 A of Ltryptophan is taken as the excluded volume for this query (i.e., the volume in which the center of no atom of a structure may fall).
For this query we found one hit in each data base. These are shown in Fig. 2c . These structures in the binding site of the tryptophan repressor are shown in Fig. 4 . It is encouraging to note that a search picked the crystal conformation of tryptophan, which is nearly superimposable with the bound conformation in the complex.
DISCUSSION
We have seen that a pharmacophore search can potentially identify: (i) compounds in the same chemical class(es) as the compounds from which the pharmacophore was derived (all examples); (ii) compounds that contain the pharmacophore, but belong to other chemical classes (many of these will have the appropriate biological activity, as seen retrospectively in the CNS pharmacophore example); and (iii) bond "frameworks" in which the important atoms are connected in novel ways or even held rigidly in the desired geometry (as in the ACE-inhibitor example).
Testing the compounds in set ii can help us to gain further insight into what molecular features are necessary and/or sufficient for activity and can aid the drug discovery process. In industrial drug discovery, the goal is to find novel "leads" in a particular therapeutic area by testing existing compounds. Set ii, being chemically diverse and yet enriched in active compounds relative to a randomly chosen set, could be a particularly fertile source of leads. (For this application, a three-dimensional version of a company's data base of proprietary compounds is especially useful, since this data base is often the sole source of patentable structures and since samples are immediately available for testing.) Fragments in set iii, which are unlikely to be found in any type of twodimensional substructure search, may suggest new directions in the design and synthesis of leads.
It is worth reviewing the limitations to pharmacophore searching. While it is generally accepted that a threedimensional representation is more "realistic" than a twodimensional "chemical structure" representation, the complication of conformational flexibility in three dimensions makes generating a pharmacophore model relatively difficult. One needs to have the structure of an appropriate drugProc. Natl. Acad. Sci. USA 86 (1989) FIG. 4. The crystal structure of tryptophan (QQQBTP) (solid lines) and the coNcoRD-generated structure of CL302086 (short dash) docked in the active site of the tryptophan repressor (dotted lines). The docking is done so that the amino nitrogen, the carboxylate carbon, and the centroid of the six-membered ring (atoms 1, 2, and 3 in Fig. ic) of the data base structures are best superimposed onto the corresponding atoms in the bound L-tryptophan (long dash).
receptor complex (for instance, an enzyme and its inhibitor) at the atomic level, or one must deduce the pharmacophore from a set of known drug molecules. In the latter case, one needs a sufficient number of semirigid molecules to define the pharmacophore geometry uniquely. Since the set of molecules used to generate the pharmacophore is necessarily limited in either case, and since many properties of the molecules are not taken into account, there is never a guarantee that the pharmacophore, once generated, is either necessary or sufficient for biological activity.
The second limitation comes from our consideration of only a single conformation per compound: the low-energy crystal conformation in the case of CCD or CONCORD'S estimate of a low-energy conformation in the case of CLFIL. These conformations are not necessarily related to the "receptor-bound" conformation represented in a query. Given the number of structures in our data bases (>200,000 for the CLFIL), it is not currently practical in terms of time or disk space to generate and store all of the low-energy conformations or to search through them on a routine basis. The consequence is that if a structure can attain a low-energy conformation consistent with the pharmacophore geometry, but that conformation (or its mirror reflection) is not the one represented in the data base, we will not find that structure. (Of course, in practice, whether or not a given conformation is consistent with a pharmacophore geometry depends on how generously one defines the bounds in the query.) On the other hand, for each structure we do find, it is almost certain that the conformation is energetically accessible.
Fortunately, to be a useful tool, pharmacophore searching need not be exhaustive, only suggestive. For any given pharmacophore, we consistently find compounds that are, in retrospect, known to be active. This leads us to expect that sets of untested compounds derived from such searches will prove enriched in actives. Since in drug discovery the frequency of finding an active compound through random testing is typically a few percent, the enrichment need be only a few fold to be ofgreat significance. Furthermore, only a few novel bond "frameworks" in which important pharmacophore atoms are held in the proper arrangement need to be found to suggest new areas for drug design and synthesis.
